GlassScriptPhysician profile
Robert T Adlerstein
NPI 1255085445
$6,276.15
in general payments reported to CMS, 2019-2025
23 companies · $1,950 in 2025
The $1,950 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $128 · 2023: $2,083 · 2024: $2,116 · 2025: $1,950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,049 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,049.36 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,459.27 | 2022-2025 | Rinvoq, Skyrizi, Humira |
| Ucb, INC. | $1,327.91 | 2022-2025 | Cimzia, Bimzelx |
| Mallinckrodt Hospital Products INC. | $488.20 | 2022-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $469.85 | 2023-2025 | |
| Amgen INC. | $466.39 | 2023-2025 | Enbrel, Otezla, Tavneos |
| Ani Pharmaceuticals, INC. | $428.09 | 2023-2025 | Purified Cortrophin Gel |
| E.R. Squibb & Sons, L.L.C. | $415.03 | 2023-2025 | Orencia |
| Janssen Biotech, INC. | $324.16 | 2023-2025 | Tremfya |
| Organon LLC | $242.90 | 2023-2025 | Hadlima, Renflexis |
| Lilly USA, LLC | $168.77 | 2023-2025 | Taltz, Zepbound |
| Glaxosmithkline, LLC. | $87.77 | 2022-2025 | Benlysta, Nucala |
| Fresenius Kabi USA, LLC | $76.08 | 2023-2025 | Idacio |
| Genzyme Corporation | $75.58 | 2023-2025 | |
| Pfizer INC. | $47.24 | 2024-2025 | |
| Kyowa Kirin, INC. | $42.62 | 2023 | Crysvita |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $31.12 | 2022 | |
| Genentech USA, INC. | $23.10 | 2023 | Rituxan, Actemra |
| Sandoz INC. | $20.90 | 2023 | Hyrimoz |
| Radius Health, INC. | $18.67 | 2025 | Tymlos |
| Kiniksa Pharmaceuticals International, Plc | $17.56 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $16.71 | 2024 | |
| Scilex Pharmaceuticals INC. | $14.22 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $14.01 | 2023 | Truxima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Adlerstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.